All In Biotech

Drug Trial Radar · NCT01895985

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

A Single-Center, Open-Label Study Evaluating the Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Lowering Intraocular Pressure Over a 24-Hour Period in Japanese Healthy Male Volunteers

Last checked: Nov 20, 2026Latest source record: May 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 2013

Primary completion

Aug 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Jul 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the effect of latanoprostene bunod dosed once daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy subjects.

Conditions

  • Intraocular Pressure

Interventions

  • Latanoprostene bunodDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. intraocular pressure (IOP)Time frame: Visit 3 (Day 14/15)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb Incorporated

    Madison, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.